Table 9.
Co-occurring Gene Mutations and Cytogenetic Abnormalities by Subgroup
| Gene | Cytogenetic Abnormality | PMF, No./Total No. (%) | PV, No./Total No. (%) | ET, No./Total No. (%) |
|---|---|---|---|---|
| JAK2 | del(20) | 12/61 (19.67)a | 3/20 (15.00) | 0/17 (0.00) |
| ASXL1 | del(20) | 7/37 (18.92)a | 0/20 (0.00) | 0/17 (0.00) |
| ASXL1 | tri(8) | 4/37 (10.81)a | 0/20 (0.00) | 0/17 (0.00) |
| SRSF2 | del(20) | 3/35 (8.57)a | 0/20 (0.00) | 0/17 (0.00) |
| TP53 | del(17) | 0/36 (0.00) | 2/19 (10.53)b | 0/17 (0.00) |
| TP53 | del(5) | 0/36 (0.00) | 2/19 (10.53)b | 0/17 (0.00) |
| JAK2 | del(17) | 0/61 (0.00) | 2/20 (10.00)b | 0/17 (0.00) |
| JAK2 | del(5) | 0/61 (0.00) | 2/20 (10.00)b | 0/17 (0.00) |
| JAK2 | tri(9) | 1/61 (1.64) | 2/20 (10.00)b | 0/17 (0.00) |
ET, essential thrombocytosis; PMF, primary myelofibrosis; PV, polycythemia vera.
a
Percentages that are highest in PMF.
b
Percentages that are highest in PV.